Previous studies have shown that OGT inhibition with OSMI‐1, an OGT inhibitor, increases sensitivity to the anticancer drug doxorubicin in HepG2 human liver cancer cells and PC‐3 prostate cancer cells [25, 26]. Here, OGT is linked to prostate carcinoma.